Avita Medical Inc. (RCEL)
$13.36-0.07%Close
BUYBULL · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $332M
- Beta
- 1.99
- P/E (TTM)
- -9.21
- Short % float
- 12.09%
- Days to cover
- 9.2
- SI change
- +0.1%
- 1W
- +2.85%
- 1M
- +31.11%
- vs SPY 1W
- +2.99%
- vs SPY 1M
- +28.60%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 15
- VALUE
- 14
- GROWTH
- 31
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC139.1%
REV YoY-
ROE231.9%
EPS YoY-
ROA-90.2%
GROSS82
OP-47
NET-57
[VALUATION]
P/E TTM-9.21
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B-14.76
P/FCF-
EV/EBITDA-10.78
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.41
ND/EBITDA-
BETA1.99
Company news
FAQ
- What is LOPJLB’s current signal on RCEL?
- LOPJLB’s latest quantitative signal on Avita Medical Inc. (RCEL) is BUY in a BULL regime. Signals are updated daily.
- What market regime is RCEL in?
- Avita Medical Inc. (RCEL) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Avita Medical Inc. (RCEL) do?
- AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The companyâs lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vi…